文献速递血栓与止血

一项在获得性血友病A患者中评估艾米珠单抗预防治疗的前瞻性、多中心、开放标签III期研究

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
PubMed 文献 · J Thromb Haemost · 2022-12-22

该前瞻性、多中心、开放标签III期研究评估艾米珠单抗在获得性血友病A患者中的疗效、安全性和药代动力学,12例接受免疫抑制治疗的患者中11例(91.7%)完成治疗,治疗期间无大出血发生,未报告出血或感染相关死亡及研究治疗相关严重不良事件,结论提示该给药方案和完成标准可能具有良好获益-风险特征。

要点

  • 艾米珠单抗按第1天6 mg/kg、第2天3 mg/kg皮下给药,第8天起每周1.5 mg/kg。
  • 12例接受免疫抑制治疗的患者中11例(91.7%)完成艾米珠单抗治疗。
  • 治疗前7例(58.3%)发生77次大出血,治疗期间无患者发生大出血。

核心结论

  • 结果提示,采用所测试的给药方案和完成标准的艾米珠单抗预防治疗在获得性血友病A患者中可能具有有利的获益-风险特征。

研究设计与样本

  • 前瞻性、多中心、开放标签III期研究(AGEHA;JapicCTI-205151),评估艾米珠单抗在获得性血友病A患者中的疗效、安全性和药代动力学。
  • 截至2021年4月23日,共纳入12例接受免疫抑制治疗的患者,其中11例(91.7%)完成艾米珠单抗治疗。
  • 艾米珠单抗皮下给药方案为第1天6 mg/kg、第2天3 mg/kg,第8天起每周1次1.5 mg/kg。
  • 预设的给药完成标准包括FVIII活性>50 IU/dL。

主要发现

  • 平均血浆艾米珠单抗谷浓度快速达到稳态(1周),达到在先天性血友病A患者中建立的有效水平(>30 μg/mL)。
  • 首次艾米珠单抗给药前,7例患者(58.3%)发生77次大出血。
  • 艾米珠单抗治疗期间,任何患者均未发生大出血。
  • 未报告出血或感染导致的死亡,也未报告任何与研究治疗相关的严重不良事件。
  • 发现1例无症状、非严重性深静脉血栓,无实验室检查提示任何高凝趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emicizumab is a bispecific antibody that mimics the cofactor function of activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A regardless of the inhibitor status; however, no prospective clinical studies have been conducted for emicizumab in patients with acquired hemophilia A (PwAHA). OBJECTIVES: To describe the primary analysis results from a prospective, multicenter, open-label phase III study evaluating the efficacy, safety, and pharmacokinetics of emicizumab in PwAHA (AGEHA; JapicCTI-205151). METHODS: Emicizumab was administered subcutaneously at 6 mg/kg on day 1 and 3 mg/kg on day 2, followed by 1.5 mg/kg once weekly from day 8 onward. Predefined criteria for the completion of dosing included FVIII activity of >50 IU/dL. RESULTS: By the cutoff date (April 23, 2021), 12 patients on immunosuppressive therapy were enrolled, and 11 of them (91.7%) completed emicizumab treatment. The mean trough plasma emicizumab concentration rapidly reached a steady state (1 week), achieving the efficacious level that was established in patients with congenital hemophilia A (>30 μg/mL). Before first emicizumab administration, 7 patients (58.3%) experienced 77 major bleeds. During emicizumab treatment, no major bleeds occurred in any patient. Neither death due to bleeding or infection nor any study treatment-related serious adverse event was reported. One asymptomatic, nonserious deep vein thrombosis was discovered with no laboratory findings indicating any trend toward hypercoagulation. CONCLUSION: These results suggest that emicizumab prophylaxis with the tested dosing regimen and completion criteria may have a favorable benefit-risk profile in PwAHA.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Shima M, Amano K, Ogawa Y, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2022. PMID: 36696195. doi:10.1016/j.jtha.2022.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。